Fmr LLC X4 Pharmaceuticals, Inc Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Fmr LLC holds 3,599 shares of XFOR stock, worth $1,871. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,599

Previous 2,531 42.2%

Holding current value

$1,871

Previous $3,000 33.33%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.58 - $1.47 $619 - $1,569	1,068 Added 42.2%	3,599 $2,000
Q1 2024 May 13, 2024	BUY	$0.72 - $1.46 $1,290 - $2,616	1,792 Added 242.49%	2,531 $3,000
Q4 2023 Feb 13, 2024	SELL	$0.61 - $0.99 $510 - $828	-837 Reduced 53.11%	739 $0
Q3 2023 Nov 13, 2023	SELL	$1.03 - $2.02 $16,022 - $31,423	-15,556 Reduced 90.8%	1,576 $1,000
Q2 2023 Aug 11, 2023	BUY	$0.82 - $2.49 $14,045 - $42,651	17,129 Added 570966.69%	17,132 $33,000
Q1 2023 May 11, 2023	BUY	$0.8 - $1.22 $2 - $3	3 New	3 $0
Q3 2022 Nov 10, 2022	BUY	$0.89 - $1.71 $8,900 - $17,100	10,000 New	10,000 $17,000
Q1 2022 May 13, 2022	SELL	$1.48 - $2.58 $78,485 - $136,819	-53,031 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.9 - $5.6 $189,620 - $558,880	-99,800 Reduced 65.3%	53,031 $121,000
Q3 2021 Nov 15, 2021	SELL	$4.53 - $6.45 $270,844 - $385,639	-59,789 Reduced 28.12%	152,831 $808,000
Q2 2021 Aug 13, 2021	BUY	$6.49 - $9.56 $1.38 Million - $2.03 Million	212,620 New	212,620 $1.38 Million

Others Institutions Holding XFOR

# of Institutions

108

Shares Held

101M

Call Options Held

418K

Put Options Held

71.7K

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $35.7M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account